First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16

Gynecol Oncol. 2016 Mar;140(3):486-93. doi: 10.1016/j.ygyno.2016.01.015. Epub 2016 Jan 13.

Abstract

Background: Platinum resistance is a dominant cause of poor outcomes in advanced ovarian cancer (OC). A mechanism of platinum resistance is the inhibition of apoptosis through phosphatidylinositol 3 kinase (PI3K) pathway activation. The role of phosphatase and tensin homolog (PTEN), a negative regulator of this pathway, as a tumor biomarker is unclear. Quantitative analysis of PTEN expression as an alternative to immunohistochemistry has not been considered.

Patients and methods: In 238 patient tumors from the NCIC-CTG trial OV.16, PTEN protein expression was quantified by Automated QUantitative Analysis (AQUA). Cox model was used to study the association between PTEN expression and clinical outcomes using a minimum p-value approach in univariate analysis. Multivariate analysis was used to adjust for clinical and pathological parameters.

Results: PTEN scores (range 13.9-192.3) of the 202 samples that passed quality control were analyzed. In univariate analysis, there was a trend suggesting an association between PTEN expression by AQUA as a binary variable (low ≤61 vs high >61) and progression free survival (HR=0.77, p=0.083), and in multivariate analysis, this association approached significance (HR=0.74, p=0.059). The relationship between quantitative PTEN expression and PFS differed (p=0.01 for interaction) by the extent of surgical debulking (residual disease (RD) <1cm or ≥1cm), with a numerically superior PFS in patients with high PTEN (23.5 vs 14.9m) only when RD<1cm (p=0.19). There was no association between PTEN levels and overall survival.

Conclusions: AQUA is a novel method to measure PTEN expression. Further study of PTEN as a biomarker in OC is warranted.

Keywords: AQUA; BRCA1; Ovarian carcinoma; PTEN.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Automation
  • Biomarkers, Tumor / analysis*
  • Cytoreduction Surgical Procedures
  • Disease-Free Survival
  • Fallopian Tubes / chemistry
  • Female
  • HeLa Cells
  • Humans
  • MCF-7 Cells
  • Middle Aged
  • Neoplasm, Residual
  • Ovarian Neoplasms / chemistry*
  • Ovarian Neoplasms / surgery*
  • PTEN Phosphohydrolase / analysis*
  • Survival Rate

Substances

  • Biomarkers, Tumor
  • PTEN Phosphohydrolase
  • PTEN protein, human